Program
emrusolmin
Also written as “TEV-56286”, “anle138b” and “TEV-56286 Test”.
Its studies are mostly in Multiple System Atrophy · Parkinson Disease, led by 2 companies.
Drug pageEmrusolmin: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Teva Pharmaceutical Industries | 53 open or running | phase 2since Aug 20, 2024 | Aug 20, 2024 | Jan 15, 2027phase 1 · NCT07674940 |
| MODAGits history only | 30 open or running | phase 1since Dec 16, 2019 | Dec 16, 2019 | none ahead |
Also a collaborator on its studies: Aptuit and Quotient Sciences.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseTeva licensed it from MODAG, for worldwide rights.Announced Oct 26, 2021 · Source: Teva and MODAG (release), Oct 26, 2021
History and studies of Teva Pharmaceutical Industries only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Oct 26, 2021Teva licensed it from MODAGLicenseWorldwide rights · announced · Teva and MODAG (release)
- Jan 25, 2022Named emrusolminINNProposed as its International Nonproprietary Name in WHO's List 126 · before, TEV-56286
- Aug 20, 2024First study: phase 2 study in Multiple System AtrophyFirst studyNCT06568237 · 349 enrolled · United States, France, Germany and more
- Oct 2, 2024Phase 1 study in Healthy ParticipantsNCT06627231 · 8 enrolled · Netherlands
- Mar 28, 2025Phase 1 study in Healthy ParticipantsNCT06911567 · 47 enrolled · United States
- Sep 26, 2025Phase 2 study in Multiple System AtrophyNCT07197866 · 200 planned · United States, France, Germany and more
- Jun 23, 2026Phase 1 study in Healthy VolunteersNCT07674940 · 69 planned · United States
Ahead
- Jan 15, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07674940
- Sep 15, 2027Primary completion: phase 2 study in Multiple System AtrophyNCT06568237
- May 3, 2029Primary completion: phase 2 study in Multiple System AtrophyNCT07197866
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 Teva Pharmaceutical Industries leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07674940Healthy Volunteers · United States | 1 | Recruiting | Jan 15, 2027 | 69 |
| NCT07197866Multiple System Atrophy · United States, France, Germany and more | 2 | Recruiting | May 3, 2029 | 200 |
| NCT06911567Healthy Participants · United States | 1 | Completed | May 22, 2025 | 47 |
| NCT06627231Healthy Participants · Netherlands | 1 | Completed | Nov 29, 2024 | 8 |
| NCT06568237Multiple System Atrophy · United States, France, Germany and more | 2 | Active, not recruiting | Sep 15, 2027 | 349 |
How it is read
Names in the registry
- “TEV-56286”, 4 entries
- “anle138b”, 2 entries
- “TEV-56286 Test”, 1 entry
- “TEV-56286 Reference”, 1 entry
- “anle138b (TEV-56286)”, 1 entry
Codes read as this program: TEV56286.
Conditions, from the studies’ own filings
- Multiple System Atrophy, 3 studies
- Parkinson Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.